The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
777
October 21, 1988
View Complete Issue         Table of Contents 2019 
Naftifine For Fungal Skin Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Naftifine For Fungal Skin Infections
October 21, 1988 (Issue: 777)
Naftifine hydrochloride 1% cream (Naftin - Herbert Laboratories), was recently approved by the US Food and Drug Administration (FDA) for topical treatment of tinea cruris and tinea corporis. It is available only by prescription.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Naftifine For Fungal Skin Infections
Article code: 777b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.